Tearing down the walls: FDA approves next generation sequencing (NGS) assays for actionable cancer genomic aberrations

Research output: Contribution to journalReview article


The United States Food and Drug Administration (FDA) recently approved the clinical use of two comprehensive 'mid-size' Next Generation Sequencing (NGS) panels calling actionable genomic aberrations in cancer. This is the first endorsement, by a regulatory body, of a new standard of care in oncology. Herein, we argue that besides its many practice-changing implications, this approval tears down the conceptual walls dividing system biology from clinical practice, diagnosis from research, prevention from therapy, cancer genetics from cancer genomics, and computational biology from empirical therapy assignment.

Original languageEnglish
Article number47
JournalJournal of Experimental and Clinical Cancer Research
Issue number1
Publication statusPublished - Mar 5 2018



  • Bioinformatics
  • Cancer screening and prevention
  • Ethics
  • Genomic aberrations
  • Next generation sequencing (NGS)
  • Patient advocacy
  • Precision medicine
  • Regulatory issues

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this